Galectin Therapeutics (GALT) Income towards Parent Company (2010 - 2026)

Galectin Therapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$6.0 million for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 37.24% year-over-year to -$6.0 million; the TTM figure through Mar 2026 stood at -$23.7 million (up 49.14% YoY), while the FY2025 annual figure was -$27.3 million, up 42.71% from the prior year.
• Income towards Parent Company was -$6.0 million for Q1 2026 at Galectin Therapeutics, down from -$5.3 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$5.3 million in Q4 2025 to a low of -$14.1 million in Q4 2024.
• Historically, Income towards Parent Company has averaged -$9.5 million across 5 years, with a median of -$9.9 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company plunged 60.32% in 2022, then jumped 62.48% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at -$10.9 million in 2022, then gained by 5.29% to -$10.3 million in 2023, then slumped by 36.14% to -$14.1 million in 2024, then surged by 62.48% to -$5.3 million in 2025, then dropped by 14.21% to -$6.0 million in 2026.
• The last three Income towards Parent Company figures came in at -$6.0 million (Q1 2026), -$5.3 million (Q4 2025), and -$6.0 million (Q3 2025), per Business Quant data.